STATEMENT UNDER 37 CFR 3.73(b) Applicant/Patent Owner: Monogram Biosciences, Inc. Filed/Issue Date: 01/19/2001 / 11/21/2006 Application No./Patent No.: 09/766,344 / 7,138,231 MEANS AND METHODS FOR MONITORING PROTEASE INHIBITOR ANTIRETROVIRAL THERAPY AND GUIDING THERAPEUTIC DECISIONS IN THE TREATMENT OF HIV/AIDS п corporation Monogram Biosciences, Inc. (Type of Assignee, e.g., corporation, partnership, university, government agency, etc. (Name of Assignee) states that it is: 1 X the assignee of the entire right, title, and interest in; an assignee of less than the entire right, title, and interest in (The extent (by percentage) of its ownership interest is the assignee of an undivided interest in the entirety of (a complete assignment from one of the joint inventors was made) the patent application/patent identified above, by virtue of either: An assignment from the inventor(s) of the patent application/patent identified above. The assignment was recorded in the United States Patent and Trademark Office at Reel ______, Frame ______, or for which a copy therefore is attached. OR B. X A chain of title from the inventor(s), of the patent application/patent identified above, to the current assignee as follows: 1. From: Inventors To: Virologic, Inc. The document was recorded in the United States Patent and Trademark Office at Reel 011843 _____, Frame 0136 ______, or for which a copy thereof is attached. To: SDS Merchant Fund, L.P. 2 From: Virologic, Inc. The document was recorded in the United States Patent and Trademark Office at Reel 013599 Frame 0791 or for which a copy thereof is attached. 3 From: SDS Merchant Fund, L.P. To: Virologic, Inc. The document was recorded in the United States Patent and Trademark Office at Reel 014066 _____, Frame 0810 _____, or for which a copy thereof is attached. Additional documents in the chain of title are listed on a supplemental sheet(s). As required by 37 CFR 3.73(b)(1)(i), the documentary evidence of the chain of title from the original owner to the assignee was, or concurrently is being, submitted for recordation pursuant to 37 CFR 3.11. [NOTE: A separate copy (i.e., a true copy of the original assignment document(s)) must be submitted to Assignment Division in accordance with 37 CFR Part 3, to record the assignment in the records of the USPTO. See MPEP 302.081 The undersigned (whose title is supplied below) is authorized to act on behalf of the assignee. Signature Attorney for Applicant Charles W. Calkins (Reg. No. 31,814) Printed or Typed Name

This collection of information is required by 37 CFR 3.7(b). The information is required to obtain or retain a benefit by the public which is 16 folia (and by the USPTO to process) an application. Confidentially is superised by 38 Lb, 62.12 and 37 CFR 11 and 11.4. This collection is estimated to take 12 minutes to complete, including processing the public processing the p

Under the Paperwork Reduction Act of 1995, no persons are required to respond to a collection of information unless it displays a valid OMB control number.

STATEMENT UNDER 37 CFR 3.73(b)

Applicant/Patent Owner: Monogram Biosciences, Inc.	
Application No./Patent No.: 09/766,344 / 7,138,231	Filed/Issue Date: 01/19/2001 / 11/21/2006
Titled: MEANS AND METHODS FOR MONITORING PROTEASE INHIBITOR ANTIRETROVIRAL THERAPY AND GUIDING THERAPEUTIC DECISIONS IN THE TREATMENT OF HIV/AIDS	
Monogram Biosciences, Inc. , a	corporation
(Name of Assignee)	(Type of Assignee, e.g., corporation, partnership, university, government agency, etc.
states that it is:	
the assignee of the entire right, title, and interest	n:
an assignee of less than the entire right, title, and (The extent (by percentage) of its ownership inter	interest in est is%); or
3.	
the patent application/patent identified above, by virtue of either.	
the United States Patent and Trademark Office a	application/patent identified above. The assignment was recorded in t Reel, or for which a
copy therefore is attached. OR	
B. X A chain of title from the inventor(s), of the patent	application/patent identified above, to the current assignee as follows:
From: Aclara Biosciences, Inc.	To: Apollo Merger Subsidiary, LLC
The document was recorded in the United States Patent and Trademark Office at	
Reel 022825 , Frame	90988 or for which a copy thereof is attached.
2. From: Apollo Merger Subsidiary, LLC	To: Virologic, Inc.
	ted States Patent and Trademark Office at
Reel 022827 , Frame	or for which a copy thereof is attached.
3. From: Virologic, Inc.	To: Monogram Biosciences, Inc.
The document was recorded in the Uni	ted States Patent and Trademark Office at
Reel 022827 , Frame	0394 or for which a copy thereof is attached.
Additional documents in the chain of title are listed on a supplemental sheet(s).	
As required by 37 CFR 3.73(b)(1)(i), the documentary evidence of the chain of title from the original owner to the assignee was, or concurrently is being, submitted for recordation pursuant to 37 CFR 3.11.	
[NOTE: A separate copy (i.e., a true copy of the original assignment document(s)) must be submitted to Assignment Division in accordance with 37 CFR Part 3, to record the assignment in the records of the USPTO. See MPEP 302.08]	
The undersigned (whose title is supplied below) is authorized	to act on behalf of the assignee.
Signature	Date
Charles W. Calkins (Reg. No. 31,814)	Attorney for Applicant
Printed or Typed Name	Title

This collection of information is required by 37 CFR 3.73(b). The information is required to obtain or retain a beands by the public which is to file (and by the USPTO to process) an application. Confidentially be governed by 38 U.S. of 22 and 37 CFR 1.11 and 1.14. This collection is estimated to take 12 minutes between the process of the collection is estimated to take 12 minutes of the total collection is estimated to take 12 minutes of the total collection is estimated to take 12 minutes of the total collection is estimated to the collection of the collection o

STATEMENT UNDER 37 CFR 3.73(b) Applicant/Patent Owner: Monogram Biosciences, Inc. Filed/Issue Date: 01/19/2001 / 11/21/2006 Application No./Patent No.: 09/766,344 / 7,138,231 MEANS AND METHODS FOR MONITORING PROTEASE INHIBITOR ANTIRETROVIRAL THERAPY AND GUIDING THERAPEUTIC DECISIONS IN THE TREATMENT OF HIV/AIDS 63 corporation Monogram Biosciences, Inc. (Type of Assignee, e.g., corporation, partnership, university, government agency, etc. (Name of Assignee) states that it is: the assignee of the entire right, title, and interest in; an assignee of less than the entire right, title, and interest in (The extent (by percentage) of its ownership interest is %); or the assignee of an undivided interest in the entirety of (a complete assignment from one of the joint inventors was made) the patent application/patent identified above, by virtue of either: An assignment from the inventor(s) of the patent application/patent identified above. The assignment was recorded in the United States Patent and Trademark Office at Reel ______, Frame ______, or for which a copy therefore is attached. OR B. X A chain of title from the inventor(s), of the patent application/patent identified above, to the current assignee as follows: 1 From: Monogram Biosciences, Inc. To: Pfizer Inc. The document was recorded in the United States Patent and Trademark Office at Reel 017681 , Frame 0183 _____, or for which a copy thereof is attached. To: Merrill Lynch Capital, ... 2. From: Monogram Biosciences, Inc. The document was recorded in the United States Patent and Trademark Office at Reel 020325 Frame 0763 or for which a copy thereof is attached. To: Monogram Biosciences, Inc. 3. From: GE Business Financial Services, Inc., ... The document was recorded in the United States Patent and Trademark Office at

As required by 37 CFR 3.73(b)(1)(i), the documentary evidence of the chain of title from the original owner to the assignee was, or concurrently is being, submitted for recordation pursuant to 37 CFR 3.11.

Additional documents in the chain of title are listed on a supplemental sheet(s).

 ∇

Printed or Typed Name

Reel 023148 Frame 0723 or for which a copy thereof is attached.

[NOTE: A separate copy (i.e., a true copy of the original assignment document(s)) must be submitted to Assignment Division in accordance with 37 CFR Part 3, to record the assignment in the records of the USPTO. See MPEP 302.08]

The undersigned (whose title is supplied below) is authorized to act on behalf of the assignee.

| Signature | Date |
| Charles W. Calkins (Reg. No. 31,814) | Attorney for Applicant

This ablaction of information is required by 37 CPR 3.7(b). The information is required to obtain or retain a benefit by the public which is to file (and by the USPTO to because) an application. Confederability by powered by 38 U.S. 6.1 22 and 37 CPR 1.11 and 1.14. This collection is estimated to take 12 minuted to the 12 minuted property of the 1.11 and 1.14. This collection is estimated to take 12 minuted to the 12 minuted property of the 1.11 and 1.14. This collection is estimated to take 12 minuted to take 2 minuted property of the 1.11 and 1.11 and

PriClasse (07-40)
Approved for use through 07/31/2012, Oblite 607-4001
U.S. Patent and Tradema's Office, U.S. DePARTMENT OF COMMENCE.
Under the Paperwork Reduction Act of 1995, no persons are required to respond to a collection of interminant unless full-pipe, a valid Dulls control h

STATEMENT UNDER 37 CFR 3.73(b)

Applicant/Patent Owner: Monogram Biosciences, Inc.	
Application No./Patent No.: 09/766,344 / 7,138,231 Filed/Issue Date: 01/19/2001 / 11/21/2006	
Titlet: MEANS AND METHODS FOR MONITORING PROTEASE INHIBITOR ANTIRETROVIRAL THERAPY AND GUIDING THERAPEUTIC DECISIONS IN THE TREATMENT OF HIV/AIDS	
Monogram Biosciences, Inc. , a corporation	
(Type of Assignee) (Type of Assignee, e.g., corporation, partnership, university, government agency, etc.	
states that it is:	
1. X the assignee of the entire right, title, and interest in;	
2. an assignee of less than the entire right, title, and interest in (The extent (by percentage) of its ownership interest is%); or	
3. the assignee of an undivided interest in the entirety of (a complete assignment from one of the joint inventors was made)	
the patent application/patent identified above, by virtue of either:	
An assignment from the inventor(s) of the patent application/patent identified above. The assignment was recorded in the United States Patent and Trademark Office at Reel, Frame, or for which a copy therefore is attached.	
OR	
B. A chain of title from the inventor(s), of the patent application/patent identified above, to the current assignee as follows:	
1. From: Pfizer, Inc. To: Monogram Biosciences, Inc.	
The document was recorded in the United States Patent and Trademark Office at Reel 023364 Frame 0305 or for which a copy thereof is attached.	
2. From: To:	
The document was recorded in the United States Patent and Trademark Office at	
Reel, Frame, or for which a copy thereof is attached.	
3. From: To:	
The document was recorded in the United States Patent and Trademark Office at	
Reel, Frame, or for which a copy thereof is attached.	
Additional documents in the chain of title are listed on a supplemental sheet(s).	
As required by 37 CFR 3.73(b)(1)(i), the documentary evidence of the chain of title from the original owner to the assignee was, or concurrently is being, submitted for recordation pursuant to 37 CFR 3.11.	
[NOTE: A separate copy (i.e., a true copy of the original assignment document(s)) must be submitted to Assignment Division in accordance with 37 CFR Part 3, to record the assignment in the records of the USPTO. See MPEP 302.08]	
The undersigned (whose title is supplied below) is authorized to act on behalf of the assignee.	
Signature Date	
Charles W. Calkins (Reg. No. 31,814) Attorney for Applicant	
Printed or Typed Name Title	

This collection of information is required by 37 CFR 3.73(b). The information is required to obtain or retain a benefit by the public which is to file (and by the USPTO to process) an application. Confidentially is governed by 35 U.S.C. 122 and 37 CFR 1.11 and 1.14. This collection is estimated to take 2 zimutuse to complete, including agenting, propriety, and submitting the completed application from the USPTO. There will say depending upon the individual case. Any common to the amount of time you require to complete this form and/or suggestions for reducing this builden, should be sent to the Chief information Officer, U.S. Patient and Trademark Officer, U.S. Patient and Trademark Officer, Statistically and the complete state of the Chief information Officer, O.S. Patient and Trademark Officer, O.S. Patient of Trademark Officer, O.S. Patient and Trademark Officer, O.S. Patient of Trademark Officer, O.S. Patient and Trademark Officer, O.S. Patient and Trademark Officer, O.S. Patient of Trademark Officer, O.S. Patient and Trademark Officer, O.S. Patient of Trademark Officer, O.S. Patient and Trademark Officer, O.S. Patient of Trademark Officer, O.S. Patient O.S. Patient O.S. for Patents, P.O. Box 1450, Alexandria, VA 22313-1450.